Effects of COX-2 and iNOS Inhibitors Alone or in Combination With Olfactory Ensheathing Cell Grafts After Spinal Cord Injury Rube ` n Lo ' pez-Vales , BSc , * Guillermo Garcı ' a-Alı ' as , PhD , * Monica S. Guzma ' n-Lenis , BSc , * Joaquim Fore 's , MD , PhD , * † Catalina Casas , PhD , * Xavier Navarro , MD , PhD , * and Enrique Verdu ' , PhD	1
Effects of COX-2 and iNOS Inhibitors Alone or in Combination With Olfactory Ensheathing Cell Grafts After Spinal Cord Injury Rube ` n Lo ' pez-Vales , BSc , * Guillermo Garcı ' a-Alı ' as , PhD , * Monica S. Guzma ' n-Lenis , BSc , * Joaquim Fore 's , MD , PhD , * † Catalina Casas , PhD , * Xavier Navarro , MD , PhD , * and Enrique Verdu '	1
Effects of COX-2 and iNOS Inhibitors Alone or in Combination With Olfactory Ensheathing Cell Grafts After Spinal Cord Injury Rube ` n Lo ' pez-Vales , BSc , * Guillermo Garcı ' a-Alı ' as , PhD , * Monica S. Guzma ' n-Lenis , BSc , * Joaquim Fore 's , MD , PhD , * † Catalina Casas , PhD , * Xavier Navarro , MD , PhD , *	1
Effects	1
COX-2 and iNOS Inhibitors Alone or in Combination With Olfactory Ensheathing Cell Grafts After Spinal Cord Injury Rube ` n Lo ' pez-Vales , BSc , * Guillermo Garcı ' a-Alı ' as , PhD , * Monica S. Guzma ' n-Lenis , BSc , * Joaquim Fore 's , MD , PhD , * † Catalina Casas , PhD , * Xavier Navarro , MD , PhD ,	12
COX-2 and iNOS Inhibitors	12
Combination With Olfactory Ensheathing Cell Grafts After Spinal Cord Injury Rube ` n Lo ' pez-Vales , BSc , * Guillermo Garcı ' a-Alı ' as , PhD , * Monica S. Guzma ' n-Lenis , BSc , * Joaquim Fore 's , MD , PhD , * † Catalina Casas , PhD , * Xavier Navarro , MD , PhD ,	50
Combination With Olfactory Ensheathing Cell Grafts After Spinal Cord Injury Rube ` n Lo ' pez-Vales , BSc , * Guillermo Garcı ' a-Alı ' as , PhD , * Monica S. Guzma ' n-Lenis , BSc , * Joaquim Fore 's , MD , PhD , * † Catalina Casas , PhD	50
Combination	50
Olfactory Ensheathing Cell Grafts After Spinal Cord Injury Rube ` n Lo ' pez-Vales , BSc , * Guillermo Garcı ' a-Alı ' as , PhD , * Monica S. Guzma ' n-Lenis , BSc , * Joaquim Fore 's , MD , PhD , *	67
Olfactory Ensheathing Cell	67
Grafts	94
Spinal Cord Injury Rube ` n Lo ' pez-Vales , BSc , * Guillermo Garcı ' a-Alı ' as , PhD , * Monica S. Guzma ' n-Lenis , BSc , * Joaquim Fore 's , MD ,	107
Spinal Cord Injury Rube ` n Lo ' pez-Vales , BSc , * Guillermo Garcı ' a-Alı ' as , PhD	107
Spinal Cord Injury Rube	107
` n Lo ' pez-Vales , BSc , * Guillermo Garcı ' a-Alı '	131
` n Lo ' pez-Vales , BSc ,	131
` n Lo ' pez-Vales	131
BSc	148
Guillermo Garcı ' a-Alı '	154
Guillermo	154
Garcı ' a-Alı '	164
Garcı '	164
a-Alı '	170
PhD	180
Monica S. Guzma ' n-Lenis , BSc , * Joaquim Fore 's , MD	186
Monica	186
S. Guzma ' n-Lenis , BSc , * Joaquim Fore 's , MD	193
S.	193
Guzma ' n-Lenis , BSc , *	196
Guzma ' n-Lenis , BSc ,	196
Guzma ' n-Lenis	196
Guzma '	196
BSc	211
Joaquim	217
Fore 's , MD	225
Fore 's	225
MD	233
PhD , *	237
PhD	237
Catalina Casas , PhD	244
Catalina	244
Casas , PhD	253
Xavier Navarro , MD , PhD	266
Xavier Navarro	266
MD	282
PhD	286
Enrique Verdu '	296
Verdu '	304
PhD	312
Study Design	318
We	332
the effects of inhibitors of COX-2 -LRB- NS398 -RRB- and iNOS -LRB- aminoguanidine -RRB- alone or in combination	343
the effects	343
inhibitors of COX-2 -LRB- NS398 -RRB- and iNOS -LRB- aminoguanidine -RRB- alone or in combination	358
inhibitors	358
COX-2 -LRB- NS398 -RRB- and iNOS -LRB- aminoguanidine -RRB-	372
COX-2	372
NS398	379
iNOS	390
aminoguanidine	396
combination	424
olfactory ensheathing cell -LRB- OEC -RRB- grafts	441
spinal cord injury in the rat	487
spinal cord injury	487
the rat	509
Objective .	518
the role	539
COX-2 and iNOS	559
spinal cord injury and an OEC transplant	580
spinal cord injury	580
an OEC transplant	603
Summary of Background Data .	622
Summary	622
Background Data	633
COX-2 and iNOS	650
a detrimental effect	671
spinal cord injury	698
contrast	721
OECs grafted into the injured spinal cord	731
OECs	731
the injured spinal cord	749
neuroprotection	781
the up-regulation of COX-2 and iNOS	814
the up-regulation	814
COX-2 and iNOS	835
Methods .	851
Photochemical injury	860
T8 spinal cord segment	896
Rats	920
local injection of OECs -LRB- n = 15 -RRB- or vehicle -LRB- DMEM ; n = 15 -RRB-	934
local injection	934
OECs -LRB- n = 15 -RRB- or vehicle -LRB- DMEM ; n = 15 -RRB-	953
OECs	953
n	959
15	963
vehicle	970
DMEM ; n = 15	979
DMEM	979
n = 15	985
n	985
15	989
Six subgroups of rats -LRB- n = 5 rats each -RRB-	994
Six subgroups	994
rats -LRB- n = 5 rats each -RRB-	1011
rats	1011
n = 5 rats each	1017
n	1017
= 5 rats each	1019
= 5 rats	1019
each	1028
given NS398 -LRB- DM-NS ; OEC-NS -RRB- , aminoguanidine -LRB- DM-AG ; OEC-AG -RRB- , or saline -LRB- DM-SS ; OEC-SS -RRB-	1039
given NS398 -LRB- DM-NS ; OEC-NS -RRB-	1039
given NS398	1039
DM-NS ; OEC-NS	1052
DM-NS	1052
OEC-NS	1059
aminoguanidine -LRB- DM-AG ; OEC-AG -RRB-	1068
aminoguanidine	1068
DM-AG ; OEC-AG	1084
DM-AG	1084
OEC-AG	1091
saline -LRB- DM-SS ; OEC-SS -RRB-	1103
saline	1103
DM-SS ; OEC-SS	1111
DM-SS	1111
OEC-SS	1118
Locomotor ability , pain sensibility , tissue sparing , and density of blood vessels	1127
Locomotor ability	1127
pain sensibility	1146
tissue sparing	1164
density of blood vessels	1184
density	1184
blood vessels	1195
Results .	1225
Two weeks following injury , motor skills and nociceptive response	1234
Two weeks	1234
injury , motor skills and nociceptive response	1254
injury	1254
motor skills	1262
nociceptive response	1279
DM-NS and DM-AG	1329
DM-SS rats	1353
The area of preserved spinal cord parenchyma	1365
The area	1365
preserved spinal cord parenchyma	1377
treated animals	1424
those given saline	1448
contrast	1471
functional outcome , tissue sparing , and density of blood vessels	1481
functional outcome	1481
tissue sparing	1501
density of blood vessels	1521
density	1521
blood vessels	1532
OEC-NS and OEC-AG	1560
OEC-SS animals	1586
Conclusions .	1602
These results	1615
COX-2 and iNOS	1652
a detrimental role	1673
spinal cord injury	1698
they	1718
an important role	1732
the neuroprotective mechanisms induced by OEC grafts after spinal cord injury	1753
the neuroprotective mechanisms	1753
OEC grafts	1795
spinal cord injury	1812
Traumatic injuries affecting the spinal cord result in loss of neural functions due to the disruption of spinal motor and sensory axonal tracts as well as to death of neurons and glia .	1833
Traumatic injuries	1833
the spinal cord result	1862
loss of neural functions due to the disruption of spinal motor and sensory axonal tracts	1888
loss	1888
neural functions due to the disruption of spinal motor and sensory axonal tracts	1896
neural functions	1896
the disruption of spinal motor and sensory axonal tracts	1920
the disruption	1920
spinal motor and sensory axonal tracts	1938
spinal motor	1938
sensory axonal tracts	1955
death of neurons and glia	1991
death	1991
neurons and glia	2000
Much of the tissue damage	2018
Much	2018
the tissue damage	2026
the primary injury	2067
secondary injury processes	2102
1 Multiple mechanisms	2130
the secondary injury following spinal cord trauma , including the activation of pro-inflammatory enzymes such as cyclooxygenase - 2 -LRB- COX-2 -RRB- and inducible nitric oxide synthase -LRB- iNOS -RRB- .2 Thus , inhibition of COX-2 and of iNOS after spinal cord trauma has been reported to exert neuroprotective effects .3,4 During the last years , we have consistently found that olfactory ensheathing cell -LRB- OEC -RRB- grafts after spinal cord injury of varying severity increase tissue sparing and improve neurologic outcome in adult rats .5 -- 8 We recently reported that in OEC-transplanted rats the expression of COX-2 and iNOS increased significantly during the first week postsurgery in comparison with vehicle-injected rats .7,8 These findings suggest that OECs promote neuroprotection of spinal cord parenchyma at least in part by modulating the expression of COX-2 and iNOS	2166
the secondary injury	2166
spinal cord trauma , including the activation of pro-inflammatory enzymes such as cyclooxygenase - 2 -LRB- COX-2 -RRB- and inducible nitric oxide synthase -LRB- iNOS -RRB- .2 Thus , inhibition of COX-2 and of iNOS after spinal cord trauma has been reported to exert neuroprotective effects .3,4 During the last years , we have consistently found that olfactory ensheathing cell -LRB- OEC -RRB- grafts after spinal cord injury of varying severity increase tissue sparing and improve neurologic outcome in adult rats .5 -- 8 We recently reported that in OEC-transplanted rats the expression of COX-2 and iNOS increased significantly during the first week postsurgery in comparison with vehicle-injected rats .7,8 These findings suggest that OECs promote neuroprotection of spinal cord parenchyma at least in part by modulating the expression of COX-2 and iNOS	2197
spinal cord trauma	2197
the activation of pro-inflammatory enzymes such as cyclooxygenase - 2 -LRB- COX-2 -RRB- and inducible nitric oxide synthase -LRB- iNOS -RRB- .2 Thus , inhibition of COX-2 and of iNOS after spinal cord trauma has been reported to exert neuroprotective effects .3,4 During the last years , we have consistently found that olfactory ensheathing cell -LRB- OEC -RRB- grafts after spinal cord injury of varying severity increase tissue sparing and improve neurologic outcome in adult rats .5 -- 8 We recently reported that in OEC-transplanted rats the expression of COX-2 and iNOS increased significantly during the first week postsurgery in comparison with vehicle-injected rats .7,8 These findings suggest that OECs promote neuroprotection of spinal cord parenchyma at least in part by modulating the expression of COX-2 and iNOS	2227
the activation of pro-inflammatory enzymes such as cyclooxygenase - 2 -LRB- COX-2 -RRB- and inducible nitric oxide synthase -LRB- iNOS -RRB- .2 Thus	2227
the activation of pro-inflammatory enzymes such as cyclooxygenase	2227
the activation	2227
pro-inflammatory enzymes such as cyclooxygenase	2245
pro-inflammatory enzymes	2245
cyclooxygenase	2278
2 -LRB- COX-2 -RRB- and inducible nitric oxide synthase -LRB- iNOS -RRB- .2 Thus	2294
2 -LRB- COX-2 -RRB-	2294
2	2294
COX-2	2297
inducible nitric oxide synthase -LRB- iNOS -RRB- .2 Thus	2308
inducible nitric oxide synthase -LRB- iNOS -RRB- .2	2308
iNOS	2341
inhibition of COX-2	2355
inhibition	2355
COX-2	2369
iNOS after spinal cord trauma has been reported to exert neuroprotective effects .3,4 During the last years , we have consistently found that olfactory ensheathing cell -LRB- OEC -RRB- grafts after spinal cord injury of varying severity increase tissue sparing and improve neurologic outcome in adult rats .5 -- 8 We recently reported that in OEC-transplanted rats the expression of COX-2 and iNOS increased significantly during the first week postsurgery in comparison with vehicle-injected rats .7,8 These findings suggest that OECs promote neuroprotection of spinal cord parenchyma at least in part by modulating the expression of COX-2 and iNOS	2382
iNOS	2382
spinal cord trauma	2393
neuroprotective effects	2439
.3,4 During the last years , we have consistently found that olfactory ensheathing cell -LRB- OEC -RRB- grafts after spinal cord injury of varying severity increase tissue sparing	2462
.3,4	2462
the last years	2474
we	2490
olfactory ensheathing cell -LRB- OEC -RRB- grafts	2522
spinal cord injury of varying severity increase tissue sparing	2568
spinal cord injury	2568
varying severity increase tissue sparing	2590
neurologic outcome	2643
adult rats	2665
.5 -- 8 We recently reported that in OEC-transplanted rats the expression of COX-2 and iNOS increased significantly during the first week postsurgery in comparison with vehicle-injected rats .7,8 These findings suggest that OECs promote neuroprotection of spinal cord parenchyma at least in part by modulating the expression of COX-2 and iNOS	2675
.5 -- 8	2675
We	2680
OEC-transplanted rats	2709
the expression of COX-2 and iNOS	2731
the expression	2731
COX-2 and iNOS	2749
the first week postsurgery in comparison	2795
the first week postsurgery	2795
comparison	2825
vehicle-injected rats	2841
.7,8	2862
These findings	2867
OECs	2895
neuroprotection of spinal cord parenchyma at least in part	2908
neuroprotection	2908
spinal cord parenchyma at least	2927
spinal cord parenchyma	2927
part	2962
the expression of COX-2 and iNOS	2981
the expression	2981
COX-2 and iNOS	2999
the aim to assess if up-regulation of COX-2 and iNOS observed in OEC-transplanted animals exerts a beneficial or a detrimental role	3020
up-regulation of COX-2 and iNOS observed in OEC-transplanted animals	3041
up-regulation	3041
COX-2 and iNOS	3058
OEC-transplanted animals	3085
a beneficial or a detrimental role	3117
a beneficial	3117
a detrimental role	3133
we	3153
selective inhibitors of COX-2 or iNOS	3169
selective inhibitors	3169
COX-2 or iNOS	3193
rats that received an acute OEC graft or only vehicle	3210
rats	3210
an acute OEC graft or only vehicle	3229
an acute OEC graft	3229
vehicle	3256
Materials and Methods OECs	3266
primary cultures of olfactory bulbs	3312
primary cultures	3312
olfactory bulbs	3332
adult female Sprague-Dawley rats	3353
detail	3437
.5	3453
8	3456
transplantation	3462
frozen cell vials	3479
37 C , washed by centrifugation -LRB- 900 rpm , 7 minutes -RRB- in Dulbecco 's modified Eagle 's medium nutrient mixture F12 Ham -LRB- DMEM ; D8900 , Sigma , St. Louis , MO -RRB- , and the pellet resuspended in the same solution	3512
37 C	3512
centrifugation -LRB- 900 rpm , 7 minutes -RRB- in Dulbecco 's modified Eagle 's medium nutrient mixture F12 Ham -LRB- DMEM ; D8900 , Sigma , St. Louis , MO -RRB- , and the pellet resuspended in the same solution	3528
centrifugation -LRB- 900 rpm , 7 minutes -RRB- in Dulbecco 's modified	3528
centrifugation -LRB- 900 rpm , 7 minutes -RRB-	3528
centrifugation	3528
900 rpm , 7 minutes	3544
900 rpm	3544
7 minutes	3553
Dulbecco 's	3567
Eagle 's medium nutrient mixture	3587
Eagle 's	3587
F12 Ham -LRB- DMEM ; D8900 , Sigma , St. Louis , MO -RRB- ,	3619
F12 Ham	3619
DMEM	3628
D8900 , Sigma , St. Louis , MO	3634
D8900	3634
Sigma	3641
St. Louis	3648
MO	3659
the pellet resuspended in the same solution	3668
the pellet	3668
the same solution	3694
The cells	3713
2 hours of thawing .7 Under pentobarbital anesthesia -LRB- 40 mg/kg , intraperitoneal -RRB- , 30 adult female Sprague-Dawley rats -LRB- 250 -- 300 g -RRB- were subjected to a dorsal laminectomy at T8 vertebra and a photochemical spinal cord lesion	3748
2 hours	3748
.7 Under pentobarbital anesthesia -LRB- 40 mg/kg , intraperitoneal -RRB- , 30 adult female Sprague-Dawley rats -LRB- 250 -- 300 g -RRB- were subjected to a dorsal laminectomy at T8 vertebra and a photochemical spinal cord lesion	3766
.7	3766
pentobarbital anesthesia -LRB- 40 mg/kg , intraperitoneal -RRB-	3775
pentobarbital anesthesia	3775
40 mg/kg , intraperitoneal	3801
40 mg/kg	3801
intraperitoneal	3811
30 adult female Sprague-Dawley rats -LRB- 250 -- 300 g -RRB-	3829
30 adult female Sprague-Dawley rats	3829
250 -- 300 g	3866
250	3866
300 g	3870
a dorsal laminectomy	3895
T8 vertebra and a photochemical spinal cord lesion	3919
T8 vertebra	3919
a photochemical spinal cord lesion	3935
The exposed spinal cord	3971
Bengal solution -LRB- 1.5 % in saline , Sigma -RRB- for 10 minutes and the excess	4016
Bengal solution -LRB- 1.5 % in saline , Sigma -RRB-	4016
Bengal solution	4016
1.5 % in saline , Sigma	4033
1.5 %	4033
saline , Sigma	4041
saline	4041
Sigma	4049
10 minutes and the excess	4060
10 minutes	4060
the excess	4075
double saline rinse	4105
The injury	4126
the dorsal surface of the cord at a light intensity of 200 kLux during 2.5 minutes by means of a 5-mm-diameter optic fiber , positioned 10 mm on top of the cord , which was connected to a halogen lamp equipped with a 100-W Xenophot halogen bulb .7 Thirty min - utes after injury	4165
the dorsal surface	4165
the cord at a light intensity of 200 kLux during 2.5 minutes by means of a 5-mm-diameter optic fiber , positioned 10 mm on top of the cord , which was connected to a halogen lamp equipped with a 100-W Xenophot halogen bulb .7 Thirty min - utes after injury	4187
the cord at a light intensity of 200 kLux during 2.5 minutes by means of a 5-mm-diameter optic fiber , positioned 10 mm on top of the cord , which was connected to a halogen lamp equipped with a 100-W Xenophot halogen bulb .7 Thirty min	4187
a light intensity of 200 kLux during 2.5 minutes	4199
a light intensity	4199
200 kLux during 2.5 minutes	4220
200 kLux	4220
2.5 minutes	4236
means of a 5-mm-diameter optic fiber , positioned 10 mm on top of the cord , which was connected to a halogen	4251
means of a 5-mm-diameter optic fiber	4251
means	4251
a 5-mm-diameter optic fiber	4260
10 mm	4300
top of the cord	4309
top	4309
the cord	4316
a halogen	4349
a 100-W Xenophot halogen bulb	4378
utes after injury	4422
utes	4422
injury	4433
15 animals	4441
four injections -LRB- 3 µL each -RRB- of DMEM	4461
four injections -LRB- 3 µL each -RRB-	4461
four injections	4461
3 µL each	4478
3 µL	4478
each	4483
DMEM	4492
the exposed spinal cord -LRB- group DMEM -RRB-	4502
the exposed spinal cord	4502
group DMEM	4527
Other 15 rats	4540
four injections of a suspension of OECs -LRB- group OEC -RRB-	4563
four injections	4563
a suspension of OECs -LRB- group OEC -RRB-	4582
a suspension	4582
OECs -LRB- group OEC -RRB-	4598
OECs	4598
group OEC	4604
a total of 180,000 cells in 12 µL of DMEM	4619
a total	4619
180,000 cells in 12 µL of DMEM	4630
180,000 cells	4630
12 µL of DMEM	4647
12 µL	4647
DMEM	4656
The suspension	4662
a glass micropipette using an air pulse microinjector -LRB- Picospitzer II , General Valve , Fairfield , NJ -RRB-	4698
a glass micropipette	4698
an air pulse microinjector -LRB- Picospitzer II , General Valve , Fairfield , NJ -RRB-	4725
an air pulse microinjector	4725
Picospitzer II	4753
General Valve	4769
Fairfield , NJ	4784
a micromanipulator	4806
the glass micropipette	4826
the dorsal surface	4877
1 mm	4896
the spinal cord	4911
Two injections	4928
1 mm rostral and another two 1mmcaudal to the lesion epicenter , each injection 0.5 mm lateral to the cord midline .7,8	4956
1 mm rostral	4956
another two 1mmcaudal to the lesion epicenter , each injection 0.5 mm lateral to the cord midline .7,8	4973
two	4981
the lesion epicenter , each injection 0.5 mm lateral to the cord midline	4998
the lesion epicenter	4998
each injection 0.5 mm lateral to the cord midline	5020
each injection 0.5 mm lateral	5020
the cord midline	5053
the wound	5083
the animals	5108
a warm environment	5133
full recovery	5158
Five minutes	5173
transplantation	5192
5 rats that had received aDMEMinjection were givenNS398 -LRB- N - -LSB- 2-cyclohexyloxy - 4-nitrophenyl -RSB- methanesulfonamide ; Tocris , 5 mg/kg , intraperitoneal ; group DM-NS -RRB- , another 5 were treated with aminoguanidine hemisulfate -LRB- Sigma , 100 mg/kg , intraperitoneal ; group DM-AG -RRB- twice a day for 3 days , and other 5	5209
5 rats	5209
aDMEMinjection	5234
givenNS398 -LRB- N - -LSB- 2-cyclohexyloxy - 4-nitrophenyl -RSB- methanesulfonamide ; Tocris , 5 mg/kg , intraperitoneal ; group DM-NS -RRB- , another 5 were treated with aminoguanidine hemisulfate -LRB- Sigma , 100 mg/kg , intraperitoneal ; group DM-AG -RRB- twice a day for 3 days	5254
givenNS398	5254
N	5265
-LSB- 2-cyclohexyloxy - 4-nitrophenyl -RSB- methanesulfonamide ; Tocris , 5 mg/kg , intraperitoneal ; group DM-NS	5267
-LSB- 2-cyclohexyloxy	5267
4-nitrophenyl -RSB- methanesulfonamide ; Tocris , 5 mg/kg , intraperitoneal	5285
4-nitrophenyl -RSB- methanesulfonamide	5285
4-nitrophenyl	5285
methanesulfonamide	5299
Tocris , 5 mg/kg , intraperitoneal	5319
Tocris , 5 mg/kg ,	5319
Tocris	5319
5 mg/kg	5327
group DM-NS	5353
another 5	5367
aminoguanidine hemisulfate -LRB- Sigma , 100 mg/kg , intraperitoneal ; group DM-AG -RRB-	5395
aminoguanidine hemisulfate	5395
Sigma , 100 mg/kg	5423
Sigma	5423
100 mg/kg	5430
intraperitoneal ; group DM-AG	5441
intraperitoneal	5441
group DM-AG	5458
twice a day	5471
3 days	5487
5	5505
saline solution -LRB- DM-SS -RRB-	5516
saline solution	5516
DM-SS	5533
The same protocol	5541
the OECgrafted animals -LRB- groups OEC-NS , OEC-AG , and OEC-SS -RRB-	5574
the OECgrafted animals	5574
groups OEC-NS , OEC-AG , and OEC-SS	5598
groups OEC-NS	5598
OEC-AG	5613
OEC-SS	5625
The doses of NS398 and aminoguanidine used	5634
The doses	5634
NS398 and aminoguanidine	5647
previous studies examining the efficacy of these compounds after spinal cord injury .3,4 Locomotor activity was evaluated prior and at 3 , 7 , and 14 days postsurgery using the open-field walking test	5691
previous studies	5691
the efficacy of these compounds	5718
the efficacy	5718
these compounds	5734
spinal cord injury .3,4 Locomotor activity was evaluated prior and at 3 , 7 , and 14 days postsurgery using the open-field walking test	5756
spinal cord injury	5756
.3,4 Locomotor activity	5774
3 , 7 , and 14 days postsurgery	5825
3	5825
7	5828
14 days postsurgery	5835
the open-field walking test	5861
Two independent examiners	5890
the hindlimb movements of the rat	5925
the hindlimb movements	5925
the rat	5951
5 minutes	5966
the locomotor function	5988
the BBB scale .9 The final score of each animal was the mean value of both examiners	6024
the BBB scale .9	6024
The final score of each animal	6040
The final score	6040
each animal	6059
the mean value of both examiners	6075
the mean value	6075
both examiners	6093
Nociceptive sensibility	6109
and 14 days postinjury with a heat-radiation method10	6154
and 14 days	6154
a heat-radiation method10	6182
a plantar algesimeter -LRB- Ugo Basile , Comerio , Italy -RRB-	6214
a plantar algesimeter	6214
Ugo Basile	6237
Comerio	6249
Italy	6258
Animals	6266
Plexiglas boxes	6289
an elevated glass plate under which the light beam of a projection lamp -LRB- 150 W -RRB- was focused onto the plantar surface of the hindpaw	6308
an elevated glass plate	6308
the light beam of a projection lamp -LRB- 150 W -RRB-	6344
the light beam	6344
a projection lamp -LRB- 150 W -RRB-	6362
a projection lamp	6362
150 W	6381
the plantar surface of the hindpaw	6405
the plantar surface	6405
the hindpaw	6428
The time to withdrawal of the heated paw	6441
The time	6441
withdrawal of the heated paw	6453
withdrawal	6453
the heated paw	6467
a time-meter coupled with infrared detectors	6503
a time-meter	6503
infrared detectors	6529
The maximal time of stimulation	6549
The maximal time	6549
stimulation	6569
40 seconds	6596
skin damage	6616
The value for a test	6629
The value	6629
a test	6643
the mean of three trials separated by 15 minutes resting periods	6654
the mean	6654
three trials separated by 15 minutes resting periods	6666
three trials	6666
15 minutes resting periods	6692
15 minutes	6692
periods	6711
Results	6720
percentage	6741
respect	6757
preoperative values	6768
Fourteen days	6789
spinal cord injury	6809
animals	6829
sodium phosphate buffer -LRB- PBS , 0.1 mol/L , pH 7.4 -RRB-	6856
sodium phosphate buffer	6856
PBS	6881
0.1 mol/L	6886
pH 7.4	6897
4 % paraformaldehyde	6916
tissue fixation	6940
The spinal cord from the lesioned segment -LRB- T8 -RRB-	6957
The spinal cord	6957
the lesioned segment -LRB- T8 -RRB-	6978
the lesioned segment	6978
T8	7000
the same buffered fixative overnight at 4 C , cryoprotected with 30 % sucrose in PBS at 4 C	7032
the same buffered fixative overnight at 4 C	7032
4	7072
30 % sucrose in PBS	7096
30 % sucrose	7096
PBS	7111
4 C	7118
rostral	7151
a cryostat at a thickness of 30 µm	7172
a cryostat	7172
a thickness of 30 µm	7186
a thickness	7186
30 µm	7201
Each section	7208
separate wells	7251
immunohistochemistry	7271
sections	7293
free-floating in trizma-buffer saline -LRB- TBS , 0.1 mol/L , pH 7.4 -RRB- with 0.5 % Triton-X-100 -LRB- Fluka , Madrid , Spain -RRB- and 5 % fetal calf serum -LRB- FCS , Biologic Industries , Israel -RRB-	7314
free-floating in trizma-buffer saline -LRB- TBS , 0.1 mol/L , pH 7.4 -RRB- with 0.5 % Triton-X-100 -LRB- Fluka , Madrid , Spain -RRB- and 5 % fetal calf serum	7314
trizma-buffer saline -LRB- TBS , 0.1 mol/L , pH 7.4 -RRB- with 0.5 % Triton-X-100 -LRB- Fluka , Madrid , Spain -RRB-	7331
trizma-buffer saline -LRB- TBS , 0.1 mol/L , pH 7.4 -RRB-	7331
trizma-buffer saline	7331
TBS	7353
0.1 mol/L	7358
pH 7.4	7369
0.5 % Triton-X-100 -LRB- Fluka , Madrid , Spain -RRB-	7382
0.5 % Triton-X-100	7382
Fluka	7401
Madrid	7408
Spain	7416
5 %	7427
FCS , Biologic Industries , Israel	7448
FCS	7448
Biologic Industries	7453
Israel	7474
1 hour	7486
24 hours at 4 °C	7515
24 hours	7515
4 °C	7527
rabbit polyclonal antibody against GFAP -LRB- AB5040 ; 1:2000 , Chemicon , Temecula , CA -RRB-	7536
rabbit polyclonal antibody	7536
GFAP -LRB- AB5040 ; 1:2000 , Chemicon , Temecula , CA -RRB-	7571
GFAP	7571
AB5040 ; 1:2000	7577
AB5040	7577
1:2000	7585
Chemicon , Temecula , CA	7593
Chemicon	7593
Temecula , CA	7603
tomato lectin -LRB- LEC ; L0651 ; 1:50 , Sigma -RRB-	7639
tomato lectin	7639
LEC ; L0651 ; 1:50 , Sigma	7654
LEC	7654
L0651 ; 1:50 , Sigma	7659
L0651	7659
1:50 , Sigma	7666
1:50	7666
Sigma	7672
washes	7686
sections	7694
donkey antirabbit Cy3 labeled immunoglobulin G or Cy2 labeled avidin -LRB- 1:200 , Jackson Immunoresearch , West Grove , PA -RRB- overnight at 4 C. Following additional washes , sections were mounted on gelatincoated slides , dehydrated in ethanol and mounted with DPX -LRB- Fluka -RRB-	7723
donkey antirabbit Cy3	7723
immunoglobulin G or Cy2 labeled avidin -LRB- 1:200 , Jackson Immunoresearch , West Grove , PA -RRB- overnight at 4 C. Following additional washes , sections were mounted on gelatincoated slides , dehydrated in ethanol and mounted with DPX -LRB- Fluka -RRB-	7753
immunoglobulin G or Cy2	7753
avidin -LRB- 1:200 , Jackson Immunoresearch , West Grove , PA -RRB- overnight at 4 C. Following additional washes , sections were mounted on gelatincoated slides , dehydrated in ethanol and mounted with DPX -LRB- Fluka -RRB-	7785
avidin	7785
1:200 , Jackson Immunoresearch , West Grove , PA	7793
1:200	7793
Jackson Immunoresearch	7800
West Grove	7824
PA	7836
overnight	7840
4	7853
C. Following additional washes , sections	7855
C.	7855
additional washes , sections	7868
additional washes	7868
sections	7887
gelatincoated slides	7912
ethanol	7948
DPX -LRB- Fluka -RRB-	7973
DPX	7973
Fluka	7978
a control	7989
some spinal cord sections from each experimental group	8000
some spinal cord sections	8000
each experimental group	8031
primary antibody or biotinylated-LEC	8078
the area of preserved spinal cord parenchyma	8161
the area	8161
preserved spinal cord parenchyma	8173
the sections stained against GFAP	8207
the sections	8207
GFAP	8236
high intensity staining	8257
reactive astrocytes	8297
the destroyed parenchyma	8344
The cord section containing the largest amount of damaged tissue	8370
The cord section	8370
the largest amount of damaged tissue	8398
the largest amount	8398
damaged tissue	8420
the lesion epicenter	8453
The epicenter section , and 5 sequential sections rostral and 5 caudal to the epicenter , with a sectionto - section distance of 300 µm ,	8475
The epicenter section	8475
5 sequential sections rostral and 5 caudal to the epicenter , with a sectionto - section distance of 300 µm	8502
5 sequential sections rostral	8502
5 sequential sections	8502
5 caudal to the epicenter , with a sectionto	8536
5 caudal	8536
the epicenter	8548
a sectionto	8568
section distance of 300 µm	8581
section distance	8581
300 µm	8601
measurements	8623
Low magnification -LRB- x40 -RRB- images were digitized , spared tissue	8637
Low magnification -LRB- x40 -RRB-	8637
Low magnification	8637
x40	8656
images	8661
tissue	8691
the preserved parenchyma	8723
a final value	8753
values of the 11 sections	8793
values	8793
the 11 sections	8803
each animal	8824
The sections stained with LEC	8837
The sections	8837
LEC	8863
blood vessel profiles	8889
High power magnification -LRB- x500 -RRB- images representing a total area of 0.04 mm2 -LRB- > 97 % of the ventral horn -RRB-	8912
High power magnification -LRB- x500 -RRB- images	8912
x500	8938
a total area of 0.04 mm2 -LRB- > 97 % of the ventral horn -RRB-	8964
a total area	8964
0.04 mm2 -LRB- > 97 % of the ventral horn -RRB-	8980
0.04 mm2	8980
> 97 % of the ventral horn	8989
>	8989
97 % of the ventral horn	8990
97 %	8990
the ventral horn	8997
both ventral horns	9031
all blood vessel profiles inside the grid	9054
all blood vessel profiles	9054
the grid	9087
Two independent subjects	9110
the measurements	9140
the same images	9162
the final value of each transverse section analyzed	9183
the final value	9183
each transverse section analyzed	9202
each transverse section	9202
the mean of both subjects	9239
the mean	9239
both subjects	9251
Values	9266
percentage with respect to uninjured animals	9290
percentage	9290
respect to uninjured animals	9306
respect	9306
uninjured animals	9317
.7 The experimental procedures adhered to the recommendations of the European Union and the U.S. Department of Health for the care and use of laboratory animals and were approved by the Ethics Committee of our institution	9334
.7	9334
The experimental procedures	9337
the recommendations of the European Union and the U.S. Department of Health	9376
the recommendations of the European Union	9376
the recommendations	9376
the European Union	9399
the U.S. Department of Health	9422
the U.S. Department	9422
Health	9445
the care and use of laboratory animals	9456
the care and use	9456
laboratory animals	9476
the Ethics Committee of our institution	9516
the Ethics Committee	9516
our institution	9540
Functional and histologic measurements	9557
a `` blinded manner , '' using a code of rats and histologic slides	9614
a `` blinded manner , ''	9614
a code of rats and histologic slides	9640
a code	9640
rats and histologic slides	9650
rats	9650
histologic slides	9659
Data	9678
the mean ± SEM	9696
Statistical analysis	9712
StatView	9753
4.5 software	9762
Statistical comparisons between groups	9776
Statistical comparisons	9776
groups	9808
nonparametric Kruskal	9828
Wallis and Mann-Whitney U tests	9851
Differences	9884
significant when P <	9912
significant	9912
P	9929
Results Figure 1 .	9940
Results	9940
Figure 1	9948
Effect of NS-398 and aminoguanidine on the open field walking test	9958
Effect	9958
NS-398 and aminoguanidine on the open field walking test	9968
NS-398 and aminoguanidine	9968
the open field walking test	9997
the open field	9997
test	10020
the BBB score	10038
DMEM -LRB- A -RRB- and OEC-transplanted animals -LRB- B -RRB-	10055
DMEM	10055
A	10061
OEC-transplanted animals	10068
B	10094
the withdrawal latency of the heated paw	10105
the withdrawal latency	10105
the heated paw	10131
the plantar algesimetry test -LRB- C -RRB-	10149
the plantar algesimetry test	10149
C	10179
both inhibitors	10193
improvement of functional outcomes	10221
improvement	10221
functional outcomes	10236
DMEM-injected animals	10259
functional recovery	10295
OEC-grafted rats	10318
P <	10337
P	10337
<	10339
0.05	10341
P <	10349
P	10349
<	10351
0.01 versus DM-SS or OEC-SS groups	10353
0.01	10353
DM-SS or OEC-SS groups	10365
Figure 2 .	10390
Figure	10390
2	10397
Representative images of transverse spinal cord sections at the epicenter site	10400
Representative images	10400
transverse spinal cord sections at the epicenter site	10425
transverse spinal cord sections	10425
the epicenter site	10460
GFAP 14 days	10501
GFAP	10501
14 days	10506
T8 photochemical injury	10520
DM-SS -LRB- A -RRB- , OEC-SS -LRB- B -RRB- , DM-NS -LRB- C -RRB- , OEC-NS -LRB- D -RRB- , DM-AG -LRB- E -RRB- , and OEC-AG -LRB- F -RRB- rats	10550
DM-SS -LRB- A -RRB- , OEC-SS -LRB- B -RRB- , DM-NS -LRB- C -RRB- , OEC-NS -LRB- D -RRB- , DM-AG -LRB- E -RRB-	10550
DM-SS -LRB- A -RRB-	10550
DM-SS	10550
A	10557
OEC-SS -LRB- B -RRB-	10561
OEC-SS	10561
B	10569
DM-NS -LRB- C -RRB-	10573
DM-NS	10573
C	10580
OEC-NS -LRB- D -RRB-	10584
OEC-NS	10584
D	10592
DM-AG -LRB- E -RRB-	10596
DM-AG	10596
E	10603
OEC-AG -LRB- F -RRB- rats	10611
OEC-AG	10611
F	10619
rats	10622
Bar	10628
1000 µm	10634
Histogram representation of the percentage of spinal cord tissue	10643
Histogram representation	10643
the percentage of spinal cord tissue	10671
the percentage	10671
spinal cord tissue	10689
the different groups evaluated -LRB- G -RRB-	10718
the different groups	10718
G	10750
P	10755
< 0.05 versus DM-SS or OECs-SS groups .	10757
<	10757
0.05 versus DM-SS or OECs-SS groups	10759
0.05	10759
DM-SS or OECs-SS groups	10771
Figure 3 .	10797
Figure	10797
3	10804
Representative images of blood vessel profiles	10807
Representative images	10807
blood vessel profiles	10832
lectin in the spinal cord	10867
lectin	10867
the spinal cord	10877
gray matter of ventral horns	10893
gray matter	10893
ventral horns	10908
the epicenter site , obtained from DM-SS -LRB- A -RRB- , OEC-SS -LRB- B -RRB- , DM-NS -LRB- C -RRB- , OEC-NS -LRB- D -RRB- , DM-AG -LRB- E -RRB- , and OEC-AG -LRB- F -RRB- rats	10925
the epicenter site	10925
DM-SS -LRB- A -RRB- , OEC-SS -LRB- B -RRB- , DM-NS -LRB- C -RRB- , OEC-NS -LRB- D -RRB- , DM-AG -LRB- E -RRB- , and OEC-AG -LRB- F -RRB- rats	10959
DM-SS -LRB- A -RRB- , OEC-SS -LRB- B -RRB- , DM-NS -LRB- C -RRB- , OEC-NS -LRB- D -RRB- , DM-AG -LRB- E -RRB-	10959
DM-SS -LRB- A -RRB-	10959
DM-SS	10959
A	10966
OEC-SS -LRB- B -RRB-	10970
OEC-SS	10970
B	10978
DM-NS -LRB- C -RRB-	10982
DM-NS	10982
C	10989
OEC-NS -LRB- D -RRB-	10993
OEC-NS	10993
D	11001
DM-AG -LRB- E -RRB-	11005
DM-AG	11005
E	11012
OEC-AG -LRB- F -RRB- rats	11020
OEC-AG	11020
F	11028
rats	11031
Histogram representation of the density of blood vessel profiles in the different groups evaluated -LRB- G -RRB- .	11037
Histogram representation	11037
the density	11065
blood vessel profiles	11080
the different groups	11105
G	11137
the increased density of blood vessels in the OEC-SS group	11146
the increased density	11146
blood vessels in the OEC-SS group	11171
blood vessels	11171
the OEC-SS group	11188
administration of NS398 or aminoguanidine	11214
administration	11214
NS398 or aminoguanidine	11232
a reduction	11268
the density of blood vessels in both DMEM - and OECtransplanted groups	11283
the density of blood vessels in both DMEM	11283
the density	11283
blood vessels in both	11298
blood vessels	11298
OECtransplanted groups	11330
Bar	11354
50 µm	11360
P <	11368
P	11368
<	11370
0.05	11372
P <	11380
P	11380
<	11382
0.01 versus DM-SS or OECs-SS groups	11384
0.01	11384
DM-SS or OECs-SS groups	11396
DMEM-injected animals	11425
acute administration of NS398 or aminoguanidine	11448
acute administration	11448
NS398 or aminoguanidine	11472
hindlimb function	11505
the open field test	11526
saline-treated rats	11560
2 weeks	11584
spinal cord injury	11598
the NS398 and aminoguanidine -	11618
the NS398	11618
aminoguanidine	11632
rats	11656
a BBB score of 15 ± 0.2 and 14 ± 0.4 respectively	11673
a BBB score of 15 ± 0.2	11673
a BBB score	11673
15 ± 0.2	11688
14 ± 0.4 respectively	11699
14 ±	11699
0.4 respectively	11702
0.4	11702
13 ± 0.3 in saline-treated animals -LRB- P < 0.05 -RRB- -LRB- Figure 1A -RRB-	11734
13 ± 0.3	11734
saline-treated animals -LRB- P < 0.05 -RRB- -LRB- Figure 1A -RRB-	11745
saline-treated animals -LRB- P < 0.05 -RRB-	11745
saline-treated animals	11745
P < 0.05	11769
P	11769
< 0.05	11771
<	11771
0.05	11773
Figure 1A	11780
The OEC grafts -LRB- OEC-SS -RRB-	11792
The OEC grafts	11792
OEC-SS	11808
significant improvement of hindlimb function	11825
significant improvement	11825
hindlimb function	11852
comparison	11873
DM-SS animals -LRB- P < 0.01 -RRB-	11889
DM-SS animals	11889
P < 0.01	11904
P	11904
< 0.01	11906
<	11906
0.01	11908
administration of NS - 398 or aminoguanidine in OEC-grafted rats	11929
administration	11929
NS - 398 or aminoguanidine in OEC-grafted rats	11947
NS - 398	11947
NS	11947
398	11951
aminoguanidine in OEC-grafted rats	11958
aminoguanidine	11958
OEC-grafted rats	11976
worsening	12000
locomotor skills	12013
transplanted rats injected with saline -LRB- Figure 1B -RRB-	12042
transplanted rats	12042
saline -LRB- Figure 1B -RRB-	12074
saline	12074
Figure 1B	12082
2 weeks	12097
the BBB scores	12118
15 ± 0.3 in group OEC-NS and 14 ± 0.5	12142
15 ±	12142
0.3	12147
group OEC-NS and 14	12154
group OEC-NS	12154
14	12171
0.5	12176
group OEC-AG	12183
the 16.5 ± 0.4	12227
group OEC-SS	12245
Photochemical spinal cord injury	12259
an increase	12301
paw withdrawal latency in the algesimetry test in all experimental groups	12316
paw withdrawal latency	12316
the algesimetry test in all experimental groups	12342
the algesimetry test	12342
all experimental groups	12366
preoperative values	12404
14 days postinjury	12428
the withdrawal latency	12448
168 % ± 17 % , 142 % ± 3 % and 146 % ± 8 % of preoperative values in DM-SS , DM-NS , and DM-AG groups , respectively -LRB- Figure 1C -RRB-	12480
168 % ± 17 %	12480
168 %	12480
± 17 %	12485
142 % ± 3 % and 146 % ± 8 % of preoperative values in DM-SS , DM-NS , and DM-AG groups , respectively -LRB- Figure 1C -RRB-	12492
142 % ± 3 % and 146 %	12492
preoperative values in DM-SS , DM-NS , and DM-AG groups , respectively -LRB- Figure 1C -RRB-	12519
preoperative values in DM-SS , DM-NS , and DM-AG groups , respectively	12519
preoperative values in DM-SS , DM-NS , and DM-AG groups	12519
preoperative values	12519
DM-SS , DM-NS , and DM-AG groups	12542
Figure 1C	12588
the other hand	12603
OEC-SS rats	12619
a significant reduction of withdrawal time	12638
a significant reduction	12638
withdrawal time	12665
comparison	12684
DM-SS-injected animals	12700
contrast	12727
administration of NS-398 or aminoguanidine in OEC-transplanted animals	12737
administration	12737
NS-398 or aminoguanidine in OEC-transplanted animals	12755
NS-398 or aminoguanidine	12755
OEC-transplanted animals	12783
a statistically significant increase	12817
the paw withdrawal latency	12857
saline-treated rats	12903
14 days	12927
withdrawal latencies averaged116 % ± 7 % ,139 % ± 2 % , and 141 %	12936
withdrawal latencies	12936
averaged116 %	12957
± 7 % ,139 % ± 2 % , and 141 %	12969
± 7 % ,139 % ± 2 %	12969
± 7 % ,139 % ±	12969
7 %	12970
,139 %	12972
141 %	12987
± 3 % of preoperative values in OEC-SS , OEC-NS , and OEC-AG groups , respectively	12992
± 3 %	12992
preoperative values in OEC-SS , OEC-NS , and OEC-AG groups	13000
preoperative values	13000
OEC-SS , OEC-NS , and OEC-AG groups	13023
Figure 1C	13072
Histologicaly	13084
14 days after injury	13102
14 days	13102
injury	13116
a cavity affecting the dorsal funiculus and the dorsal gray matter up to the central canal	13124
a cavity	13124
the dorsal funiculus and the dorsal	13143
the dorsal funiculus	13143
the dorsal	13168
the central canal	13197
transverse spinal cord sections	13230
animals of group DM-SS -LRB- Figure 2A -RRB-	13265
animals	13265
group DM-SS -LRB- Figure 2A -RRB-	13276
group DM-SS	13276
Figure 2A	13289
Tissue sparing assessment	13301
Tissue	13301
assessment	13316
administration of NS - 398 or aminoguanidine in DMEM-injected animals	13339
administration	13339
NS - 398 or aminoguanidine in DMEM-injected animals	13357
NS - 398	13357
NS	13357
398	13361
aminoguanidine in DMEM-injected animals	13368
aminoguanidine	13368
DMEM-injected animals	13386
the amount of preserved cord parenchyma	13432
the amount	13432
preserved cord parenchyma	13446
lateral funiculi and gray matter	13483
lateral funiculi	13483
gray matter	13504
comparison with saline-treated rats -LRB- Figure 2C , E -RRB-	13520
comparison	13520
saline-treated rats -LRB- Figure 2C , E -RRB-	13536
saline-treated rats	13536
Figure 2C , E	13557
Figure 2C	13557
E	13568
The proportion of spinal cord tissue	13572
The proportion	13572
spinal cord tissue	13590
49 % ± 1.5 % , 57 % ± 1.1 % , and 56 % ± 1.6 %	13625
49 % ± 1.5 %	13625
49 %	13625
± 1.5 %	13629
57 % ± 1.1 %	13637
57 %	13637
± 1.1 %	13641
56 % ± 1.6 %	13653
56 %	13653
± 1.6 %	13657
DM-SS , DMNS , and DM-AG groups	13667
spinal cord sections from OEC-SS rats	13715
spinal cord sections	13715
OEC-SS rats	13741
the cavity	13754
the dorsal and partially dorsolateral funiculi , whereas ventrolateral and ventral funiculi appeared unaffected -LRB- Figure 2B -RRB-	13774
the dorsal	13774
partially dorsolateral funiculi , whereas ventrolateral and ventral funiculi appeared unaffected -LRB- Figure 2B -RRB-	13789
partially dorsolateral funiculi , whereas ventrolateral and ventral funiculi appeared unaffected	13789
partially dorsolateral funiculi	13789
ventrolateral and ventral funiculi	13830
ventrolateral	13830
ventral funiculi	13848
Figure 2B	13886
The amount of preserved cord	13898
The amount	13898
preserved cord	13912
group DM-SS , further demonstrating the neuroprotective effect exerted by grafted OECs .6,7 However	13960
group DM-SS	13960
further demonstrating the neuroprotective effect exerted by grafted OECs .6,7 However	13973
further	13973
the neuroprotective effect exerted by grafted OECs .6,7 However	13995
the neuroprotective effect	13995
OECs .6,7 However	14041
OECs .6,7	14041
administration of NS-398 or aminoguanidine	14059
administration	14059
NS-398 or aminoguanidine	14077
an increase in the lesion size	14114
an increase	14114
the lesion size	14129
OEC-transplanted rats	14148
Larger cavities involving dorsal funiculi , lateral funiculi , and gray matter	14171
Larger cavities	14171
dorsal funiculi , lateral funiculi , and gray matter	14197
dorsal funiculi	14197
lateral funiculi	14214
gray matter	14236
spinal cords of OEC-NS and OEC-AG rats -LRB- Figure 2D , F -RRB-	14265
spinal cords	14265
OEC-NS and OEC-AG rats -LRB- Figure 2D , F -RRB-	14281
OEC-NS and OEC-AG rats	14281
Figure 2D , F	14305
Figure 2D	14305
F	14316
The percentage of spinal cord tissue sparing	14320
The percentage	14320
spinal cord tissue sparing	14338
spinal cord tissue	14338
groups OEC-NS -LRB- 56 % ± 1.0 % -RRB- and OEC-AG -LRB- 52 % ± 2.0 % -RRB-	14392
groups OEC-NS -LRB- 56 % ± 1.0 % -RRB-	14392
groups OEC-NS	14392
56 % ± 1.0 %	14407
56 %	14407
± 1.0 %	14411
OEC-AG -LRB- 52 % ± 2.0 % -RRB-	14423
OEC-AG	14423
52 % ± 2.0 %	14431
52 %	14431
± 2.0 %	14435
group OEC-SS -LRB- 62.3 % ± 2.5 % -RRB- -LRB- Figure 2G -RRB-	14451
group OEC-SS -LRB- 62.3 % ± 2.5 % -RRB-	14451
group OEC-SS	14451
62.3 % ± 2.5 %	14465
62.3 %	14465
± 2.5 %	14471
Figure 2G	14480
spinal cord sections at the injury site	14495
spinal cord sections	14495
the injury site	14519
the density of blood vessel profiles in the ventral horn of DM-SS animals	14536
the density	14536
blood vessel profiles in the ventral horn of DM-SS animals	14551
blood vessel profiles	14551
the ventral horn of DM-SS animals	14576
the ventral horn	14576
DM-SS animals	14596
98 % ± 2 %	14623
98 %	14623
± 2 %	14627
±	14627
that found in control intact cords , whereas administration of COX-2 or iNOS inhibitors significantly decreased the blood vessel density to 86 % ± 4 % and 76 % ± 5 % in DM-NS and DM-AG groups , respectively -LRB- P < 0.05 -RRB- -LRB- Figure 3C , E , G -RRB-	14636
that	14636
control intact cords	14650
administration of COX-2 or iNOS inhibitors	14680
administration	14680
COX-2 or iNOS inhibitors	14698
the blood vessel density	14747
86 % ± 4 % and 76 % ± 5 %	14775
86 % ± 4 % and 76 %	14775
DM-NS and DM-AG groups , respectively -LRB- P < 0.05 -RRB- -LRB- Figure 3C , E , G -RRB-	14800
DM-NS and DM-AG groups , respectively -LRB- P < 0.05 -RRB-	14800
DM-NS and DM-AG groups , respectively	14800
DM-NS and DM-AG groups	14800
P < 0.05	14838
P	14838
< 0.05	14840
<	14840
0.05	14842
Figure 3C	14849
E	14860
G	14863
group OEC-SS	14870
the density of blood vessel profiles	14884
the density	14884
blood vessel profiles	14899
132 % ± 6 %	14932
132 %	14932
intact animals	14962
rats of group DM-SS -LRB- P < 0.01 -RRB- -LRB- Figure 3B -RRB-	14985
rats	14985
group DM-SS -LRB- P < 0.01 -RRB- -LRB- Figure 3B -RRB-	14993
group DM-SS -LRB- P < 0.01 -RRB-	14993
group DM-SS	14993
P < 0.01	15006
P	15006
< 0.01	15008
<	15008
0.01	15010
Figure 3B	15017
contrast	15032
administration of NS-398 or aminoguanidine in OEC-transplanted animals	15042
administration	15042
NS-398 or aminoguanidine in OEC-transplanted animals	15060
NS-398 or aminoguanidine	15060
OEC-transplanted animals	15088
a significant reduction	15125
the density of blood vessels to mean values of 79 % ± 3 % and 84 % ± 2 % in OEC-NS and OEC-AG groups , respectively -LRB- P < 0.01 -RRB- -LRB- Figure 3D , F , G -RRB-	15152
the density	15152
blood vessels to mean values of 79 % ± 3 % and 84 % ± 2 % in OEC-NS and OEC-AG groups , respectively -LRB- P < 0.01 -RRB- -LRB- Figure 3D , F , G -RRB-	15167
blood vessels to mean values of 79 % ± 3 % and 84 % ± 2 % in OEC-NS and OEC-AG groups , respectively -LRB- P < 0.01 -RRB-	15167
blood vessels	15167
values of 79 %	15189
values	15189
79 %	15199
± 3 % and 84 % ± 2 %	15203
± 3 % and 84 % ±	15203
OEC-NS and OEC-AG groups	15224
P < 0.01	15264
P	15264
< 0.01	15266
<	15266
0.01	15268
Figure 3D	15275
F	15286
G	15289
Discussion The results of the present work	15294
Discussion The results	15294
Discussion	15294
The results	15305
the present work	15320
acute administration of NS398 or aminoguanidine , two inhibitors of COX-2 and iNOS	15351
acute administration	15351
NS398 or aminoguanidine , two inhibitors of COX-2 and iNOS	15375
NS398 or aminoguanidine	15375
two inhibitors of COX-2 and iNOS	15400
two inhibitors	15400
COX-2 and iNOS	15418
functional recovery	15457
neuroprotection	15499
photochemical spinal cord damage	15521
the most novel and striking finding of this work	15564
the most novel and striking finding	15564
this work	15603
combination of NS398 or aminoguanidine administration with an acute transplantation of OECs after spinal cord injury	15621
combination	15621
NS398 or aminoguanidine administration with an acute transplantation of OECs after spinal cord injury	15636
NS398 or aminoguanidine administration	15636
an acute transplantation of OECs after spinal cord injury	15680
an acute transplantation	15680
OECs after spinal cord injury	15708
OECs	15708
spinal cord injury	15719
antinergic effects	15748
Both NS398 and aminoguanidine treatment in rats that had received an OEC graft	15768
Both NS398 and aminoguanidine treatment	15768
rats that had received an OEC graft	15811
rats	15811
an OEC graft	15834
functional outcome , tissue sparing and blood vessel formation	15855
outcome , tissue sparing and blood vessel	15866
outcome	15866
tissue sparing	15875
blood vessel	15894
comparison	15920
untreated OEC-transplanted rats	15936
The outcome differences between our experimental groups	15969
The outcome differences	15969
our experimental groups	16001
We	16069
a series of studies	16082
a series	16082
studies	16094
photochemical injury	16108
the rat spinal cord over the last years	16132
the rat spinal cord	16132
the last years	16157
consistent and repetitive results of functional deficits and tissue damage ,5 -- 8	16186
consistent and repetitive results of functional deficits	16186
consistent and repetitive results	16186
functional deficits	16223
tissue damage ,5 -- 8	16247
tissue damage	16247
,5 -- 8	16260
an adequate experimental model for assaying treatments	16280
an adequate experimental model	16280
assaying treatments	16315
the efficacy of spinal cord injury treatment in laboratory animals	16351
the efficacy	16351
spinal cord injury treatment in laboratory animals	16367
spinal cord injury treatment	16367
laboratory animals	16399
now	16441
This	16446
increasing interest in the scientific literature	16458
increasing interest	16458
the scientific literature	16481
combined therapies , in the search for synergic or additive beneficial effects , which are low with single therapies	16521
combined therapies	16521
the search for synergic or additive beneficial effects , which are low with single therapies	16544
the search	16544
synergic or additive beneficial effects , which are low with single therapies	16559
synergic or additive beneficial effects	16559
single therapies	16619
Two weeks following the photochemical lesion performed	16637
Two weeks	16637
the photochemical lesion performed	16657
the photochemical lesion	16657
rats that received vehicle injection and were treated with NS398 or aminoguanidine	16693
rats	16693
vehicle injection	16712
NS398 or aminoguanidine	16752
significantly higher BBB score and slightly higher pain sensibility	16783
significantly higher BBB score	16783
slightly higher pain sensibility	16818
rats given saline solution	16856
rats	16856
saline solution	16867
Histologicaly , spinal cord tissue sparing	16884
Histologicaly	16884
spinal cord tissue sparing	16899
spinal cord tissue	16899
the density of blood vessel profiles	16955
the density	16955
blood vessel profiles	16970
rats treated with NS398 or aminoguanidine in comparison with those given saline	17007
rats	17007
NS398 or aminoguanidine	17025
comparison with those given saline	17052
comparison	17052
those given saline	17068
These results	17088
general agreement with previous studies	17109
general agreement	17109
previous studies	17132
NS3983 or aminoguanidine4	17162
neuroprotection	17197
acute spinal cord injury and slightly improved neurologic recovery	17219
acute spinal cord injury	17219
slightly improved neurologic recovery	17248
Metabolites of COX and iNOS pathways	17287
Metabolites	17287
COX and iNOS pathways	17302
COX	17302
iNOS pathways	17310
local mediators in regulating inflammation , immune function , vascular tone , and neurotransmission .2 Although the role of COX-2 and iNOS after injury has not been completely elucidated , pharmacologic inhibition of these enzymes has been reported to reduce the lesion size and functional deficits in several models of CNS lesions .2 The contribution of COX-2 to secondary cell death events following spinal cord injury seems to be mediated by production of superoxide anions during the synthesis of prostanoids from arachidonic acid .2 On the other hand , the neurotoxic effects of iNOS are thought to be caused by the reaction of NO with superoxide anion , leading to the formation of peroxynitrite .11 Both superoxide anion and peroxynitrite are potent oxidative agents and induce highly damaging effects on lipids , proteins , and DNA , exacerbating glial and neuronal cell death .12 Inhibition of these pathways	17335
local mediators	17335
inflammation , immune function , vascular tone , and neurotransmission .2	17365
inflammation	17365
immune function	17379
vascular tone	17396
neurotransmission .2	17415
the role of COX-2 and iNOS after injury	17444
the role	17444
COX-2 and iNOS after injury	17456
COX-2 and iNOS	17456
injury	17477
pharmacologic inhibition of these enzymes	17520
pharmacologic inhibition	17520
these enzymes	17548
the lesion size	17590
functional deficits in several models of CNS lesions	17610
functional deficits	17610
several models of CNS lesions	17633
several models	17633
CNS lesions	17651
.2	17662
The contribution of COX-2 to secondary cell	17665
The contribution	17665
COX-2 to secondary cell	17685
COX-2	17685
secondary cell	17694
death events following spinal cord injury	17709
death events	17709
spinal cord injury	17732
production of superoxide anions	17775
production	17775
superoxide anions	17789
the synthesis of prostanoids from arachidonic acid .2 On the other hand , the neurotoxic effects of iNOS are thought to be caused by the reaction of NO with superoxide anion	17814
the synthesis	17814
prostanoids from arachidonic acid .2 On the other hand , the neurotoxic effects of iNOS are thought to be caused by the reaction of NO with superoxide anion	17831
prostanoids	17831
arachidonic acid .2 On the other hand , the neurotoxic effects of iNOS are thought to be caused by the reaction of NO with superoxide anion	17848
arachidonic acid .2	17848
the other hand	17870
the neurotoxic effects of iNOS	17886
the neurotoxic effects	17886
iNOS	17912
the reaction of NO	17945
the reaction	17945
NO	17961
superoxide anion	17969
the formation of peroxynitrite .11 Both superoxide anion and peroxynitrite are potent oxidative agents and induce highly damaging effects on lipids , proteins , and DNA	17998
the formation of peroxynitrite .11	17998
the formation	17998
peroxynitrite .11	18015
superoxide anion and peroxynitrite are potent oxidative agents and induce highly damaging effects on lipids , proteins , and DNA	18037
superoxide anion and peroxynitrite	18037
potent oxidative agents	18076
highly damaging effects	18111
lipids , proteins , and DNA	18138
glial and neuronal cell death	18178
.12 Inhibition of these pathways	18207
.12 Inhibition	18207
these pathways	18225
the neuroprotective effects observed with NS398 and aminoguanidine administration early after injury	18252
the neuroprotective effects	18252
NS398 and aminoguanidine administration early	18294
injury	18346
COX-2 and iNOS	18363
the pathophysiology of spinal cord injury , both enzymes	18392
the pathophysiology	18392
spinal cord injury , both enzymes	18415
spinal cord injury	18415
enzymes	18440
neuroprotective actions	18463
It	18488
PGE2 , the major product of COX-2 activity ,	18514
PGE2	18514
the major product of COX-2 activity	18520
the major product	18520
COX-2 activity	18541
neuroprotection	18566
the CNS	18589
its binding with the EP2 receptor and increasing cAMP levels in neurons	18615
its binding with the EP2 receptor	18615
its binding	18615
the EP2 receptor	18632
increasing cAMP levels in neurons	18653
increasing cAMP levels	18653
neurons	18679
glial cells ,13	18691
glial cells	18691
,13	18702
myeloperoxydase activity and TNF release in neutrophils ,14	18715
myeloperoxydase activity and TNF release	18715
neutrophils ,14	18759
neutrophils	18759
,14	18770
up-regulation of vascular endothelial growth factor -LRB- VEGF -RRB-	18787
up-regulation	18787
vascular endothelial growth factor -LRB- VEGF -RRB-	18804
vascular endothelial growth factor	18804
VEGF	18840
.15	18845
the other hand	18852
NO	18868
beneficial effects following CNS injury	18888
beneficial effects	18888
CNS injury	18917
peroxynitrites	18935
thiol groups of NMDA receptors16 and caspases	18965
thiol groups	18965
NMDA receptors16 and caspases	18981
,17 inhibiting their function and mediating protection against excitotoxicity	19010
,17	19010
their function	19025
protection against excitotoxicity	19054
protection	19054
excitotoxicity	19073
apoptosis .2,18,19	19092
addition	19113
NO	19123
up-regulation of VEGF .20,21	19142
up-regulation	19142
VEGF .20,21	19159
COX-2 and iNOS	19181
a common feature in that	19202
a common feature	19202
that	19222
enzymes	19232
the expression of VEGF , the main cytokine inducing angiogenesis	19249
the expression	19249
VEGF , the main cytokine inducing angiogenesis	19267
VEGF	19267
the main cytokine inducing angiogenesis	19273
the main cytokine	19273
angiogenesis	19300
COX-2 and iNOS	19324
a synergic effect	19355
the induction of VEGF up-regulation and blood vessel formation .22 After spinal cord injury , neoangiogenesis plays an important role in increasing blood flow at the lesioned site , where hypoxia and hypoglycemia occur .20,21 VEGF administration after spinal cord injury has been reported to promote neuroprotection and to reduce axonal dieback	19376
the induction	19376
VEGF up-regulation and blood vessel formation .22 After spinal cord injury , neoangiogenesis plays an important role in increasing blood flow at the lesioned site , where hypoxia and hypoglycemia occur .20,21 VEGF administration after spinal cord injury has been reported to promote neuroprotection and to reduce axonal dieback	19393
VEGF up-regulation and blood vessel formation	19393
.22	19438
spinal cord injury , neoangiogenesis	19448
spinal cord injury	19448
neoangiogenesis	19468
an important role	19490
blood flow	19522
the lesioned site , where hypoxia and hypoglycemia occur .20,21 VEGF administration after spinal cord injury has been reported to promote neuroprotection and to reduce axonal dieback	19536
the lesioned site	19536
hypoxia and hypoglycemia	19561
.20,21 VEGF administration	19591
spinal cord injury	19624
neuroprotection	19672
axonal dieback	19702
23 OECs	19718
VEGF	19746
.24	19759
we7 and others25	19773
OECs transplanted into the injured spinal cord	19804
OECs	19804
the injured spinal cord	19827
up-regulation of VEGF in astrocytes	19859
up-regulation	19859
VEGF in astrocytes	19876
VEGF	19876
astrocytes	19884
neoangiogenic response , specially by 7 days postlesion	19909
neoangiogenic response	19909
specially by 7 days postlesion	19933
7 days	19946
We	19965
the increased neoangiogenesis observed in OECtransplanted rats	19983
the increased neoangiogenesis	19983
OECtransplanted rats	20025
up-regulation of VEGF mediated by the increased expression of COX-2 and iNOS	20057
up-regulation	20057
VEGF mediated by the increased expression of COX-2 and iNOS	20074
VEGF	20074
the increased expression of COX-2 and iNOS	20091
the increased expression	20091
COX-2 and iNOS	20119
the peak expression of COX-2 and iNOS	20159
the peak expression	20159
COX-2 and iNOS	20182
3 days	20210
the expression of both enzymes at 7 days	20218
the expression	20218
both enzymes at 7 days	20236
both enzymes	20236
7 days	20252
OEC grafted rats in comparison with DM injected rats .7,8 In the present study , we observed that administration of NS398 or aminoguanidine after spinal cord injury reduced the density of blood vessels to a similar degree in both OECs - and DMEM-injected animals , indicating that inhibition of COX-2 or iNOS reduces angiogenesis	20287
OEC	20287
rats in comparison with DM	20299
rats	20299
comparison with DM	20307
comparison	20307
DM	20323
rats .7,8 In the present study , we observed that administration of NS398 or aminoguanidine after spinal cord injury reduced the density of blood vessels to a similar degree in both OECs - and DMEM-injected animals	20335
rats .7,8 In the present study , we observed that administration of NS398 or aminoguanidine after spinal cord injury reduced the density of blood vessels to a similar degree in both OECs	20335
rats .7,8	20335
the present study	20347
we	20366
administration of NS398 or aminoguanidine after spinal cord injury	20383
administration	20383
NS398 or aminoguanidine after spinal cord injury	20401
NS398 or aminoguanidine	20401
spinal cord injury	20431
the density of blood vessels	20458
the density	20458
blood vessels	20473
a similar degree	20490
OECs	20515
DMEM-injected animals	20525
inhibition of COX-2 or iNOS	20564
inhibition	20564
COX-2 or iNOS	20578
angiogenesis	20600
DMEM-injected animals	20639
inhibition of COX-2 or iNOS	20661
inhibition	20661
COX-2 or iNOS	20675
a neuroprotective role	20696
OECs-transplanted animals	20723
it	20749
the beneficial effects observed with the cell graft alone	20765
the beneficial effects	20765
the cell graft	20802
These results	20824
iNOS or COX-2	20852
a dual role in spinal cord injuries	20875
a dual role	20875
spinal cord injuries	20890
their level of expression and the angiogenic-induced response	20924
their level	20924
expression and the angiogenic-induced response	20939
expression	20939
the angiogenic-induced response	20954
spinal cord injury	20993
up-regulation of COX-2 and iNOS	21013
up-regulation	21013
COX-2 and iNOS	21030
an effective neoangiogenic response	21081
harmful mechanisms caused by both enzymes	21129
harmful mechanisms	21129
enzymes	21163
their beneficial actions	21184
an ongoing spread of damage	21226
an ongoing spread	21226
damage	21247
We	21255
the higher up-regulation of COX-2 and iNOS induced by OEC-transplants	21275
the higher up-regulation	21275
COX-2 and iNOS	21303
OEC-transplants	21329
an appropriate neoangiogenic response	21375
protective effects	21420
detrimental effects caused by COX-2 and iNOS activity	21458
detrimental effects	21458
COX-2 and iNOS activity	21488
A similar pattern	21513
IL-6	21554
CNS injury	21565
IL-6 reactivity	21590
anti-rat IL-6 antibodies	21612
tissue sparing	21647
spinal cord injury	21668
,26 whereas overexpression of IL-6 in transgenic mice also resulted in neuroprotection after brain injury .27,28	21686
,26	21686
overexpression of IL-6 in transgenic mice	21698
overexpression	21698
IL-6 in transgenic mice	21716
IL-6	21716
transgenic mice	21724
neuroprotection	21757
brain injury .27,28	21779
